gdc
FDA Approvals, News & UpdatesLung CancerNewsworthy

Gilotrif Approved as First Treatment for Metastatic Lung Cancer and EGFR Mutations

May 2018 – Cancer Biomarkers and Molecular Testing

On January 12, 2018, the FDA approved Gilotrif (afatinib; from Boehringer Ingelheim) for use as the first treatment in patients with metastatic non–small-cell lung cancer (NSCLC) associated with nonresistant EGFR mutations, as identified by an FDA-approved test.

Gilotrif was previously approved for patients with metastatic NSCLC and EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test, and for metastatic, squamous NSCLC that progressed with platinum-based chemotherapy.

This new indication for Gilotrif was based on durable responses in patients with metastatic NSCLC and nonresistant EGFR mutations other than exon 19 deletions or exon 21 L858R substitutions.

Overall, 66% of patients responded to treatment with Gilotrif. Among the 21 patients who responded to treatment, the response lasted 12 months or longer in half of the patients and 18 months or longer in one-third of patients.

The most common side effects with Gilotrif are diarrhea, rash, paronychia, dry skin, decreased appetite,nausea, vomiting, and pruritus.

Share this:

Recommended For You
FDA Approvals, News & UpdatesLymphoma
FDA Approved Breyanzi, Novel Gene Therapy, for Large B-Cell Lymphoma
In February 2021, the FDA approved Breyanzi (lisocabtagene maraleucel; from Juno Therapeutics), a new CAR T-cell therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.
FDA Approvals, News & UpdatesFollicular LymphomaLymphoma
FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma
In February 2021, the FDA approved Ukoniq (umbralisib; from TG Therapeutics), an oral kinase inhibitor, for the treatment of adults with relapsed or refractory marginal-zone lymphoma (MZL) or with relapsed or refractory follicular lymphoma.
FDA Approvals, News & UpdatesFollicular Lymphoma
Yescarta First Gene Therapy Approved for Follicular Lymphoma
In March 2021, the FDA approved a new indication for Yescarta (axicabtagene ciloleucel; from Kite Pharma), a CAR T-cell therapy, for the treatment of patients with relapsed or refractory follicular lymphoma who have received 2 or more lines of systemic therapy.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Abecma, First CAR T-Cell Therapy for Multiple Myeloma
In March 2021, the FDA approved Abecma (idecabtagene vicleucel; from Bristol Myers Squibb/Bluebird Bio), a BCMA-directed, genetically modified CAR T-cell therapy, for the treatment of adults with multiple myeloma whose disease did not respond to, or returned, after 4 or more lines of therapy.
Last modified: July 20, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country